Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity.
Sandra Gofinet PasotoAri Stiel Radu HalpernLissiane Karine Noronha GuedesAna Cristina de Medeiros RibeiroEmily Figueiredo Vieira Neves YukiCarla Gonçalves Schahin SaadClovis Artur Almeida da SilvaLeonard de Vinci Kanda KupaLorena Elizabeth Betancourt VillamarínVictor Adriano de Oliveira MartinsCarolina Campagnoli Machado Freire MartinsGiordano Bruno Henriques DevezaElaine Pires LeonCleonice BuenoTatiana do Nascimento PedrosaRoseli Eliana Beseggio SantosRenata S NovellinoNádia Emi AikawaEloisa S BonfaPublished in: Clinical rheumatology (2022)
ClinicalTrials.gov Identifier: NCT04754698. Key Points • Sinovac-CoronaVac vaccine is safe in pSS, without a detrimental effect on systemic disease activity, and has a moderate short-term humoral response • A booster dose should be considered in these patients.
Keyphrases